Hormonal
Semaglutide 2.4 mg once weekly improves symptoms, exercise capacity, and reduces inflammation in patients with obesity-phenotype heart failure with preserved ejection fraction (HFpEF) across all obesity classes (BMI 30-34.9, 35-39.9, and ≥40 kg/m²), with clinical benefits directly proportional to the magnitude of weight loss.
If you have heart failure with preserved ejection fraction and obesity, semaglutide (2.4 mg weekly) is a proven treatment that improves your heart symptoms, exercise ability, and inflammation. The more weight you lose, the more you benefit, regardless of whether your obesity is Class I, II, or III. This treatment works best when combined with a moderate caloric deficit (500 kcal/day) and regular physical activity.
In semaglutide-treated patients, improvements in KCCQ-CSS, 6MWD and CRP were greater with larger body weight reduction... Collectively, these data support semaglutide-mediated weight loss as a key treatment strategy in patients with obesity phenotype of HFpEF.
Why this rating
Based on a prespecified analysis of a large, randomized, double-blind, placebo-controlled trial (STEP-HFpEF) with 529 participants.
Source
Semaglutide in HFpEF across obesity class and by body weight reduction: a prespecified analysis of the STEP-HFpEF trial
Barry A. Borlaug et al. · Nature Medicine · 2023
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →